

Special Issue

Protoparvoviruses: Friends or Foes?

Message from the Guest Editors

Accumulating evidence has demonstrated that some members of the *Parvoviridae* family, in particular some *rodent Protoparvoviruses* have natural anticancer activities, while being nonpathogenic to humans. However, a number of Parvoviruses cause diseases in humans and animals and recently, deep sequencing and metagenomic techniques have allowed the discovery of several novel parvoviruses, suspected of being pathogenic; in particular bufaviruses. This Special Issue of *Viruses* will explore the impact of Protoparvovirus evolution on the outcome of the interactions of these agents with host cells and organisms. Topics may include studies on various steps of the viral cycle, virus adaptation, immune responses to infection and mechanisms of virus immune evasion, clinical presentation of virus infection, and strategies for vaccine development.

Dr. Jürg Nüesch
Guest editors

Guest Editors

Dr. Christiane Dinsart
DKFZ, Abt F010, Im Neuenheimer Feld 242, D-69120 Heidelberg,
Germany

Dr. Jürg P.F. Nüesch
Infection, Inflammation and Cancer (IIC), Department Virus-Associated
Carcinogenesis (F170) German Cancer Research Center (DKFZ),
Heidelberg, Germany

Deadline for manuscript submissions

closed (31 January 2018)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/8656

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).